JP2023516280A5 - - Google Patents

Info

Publication number
JP2023516280A5
JP2023516280A5 JP2022548140A JP2022548140A JP2023516280A5 JP 2023516280 A5 JP2023516280 A5 JP 2023516280A5 JP 2022548140 A JP2022548140 A JP 2022548140A JP 2022548140 A JP2022548140 A JP 2022548140A JP 2023516280 A5 JP2023516280 A5 JP 2023516280A5
Authority
JP
Japan
Prior art keywords
binder
seq
nucleic acid
acid molecule
recombinant vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548140A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516280A (ja
Filing date
Publication date
Priority claimed from GBGB2020508.4A external-priority patent/GB202020508D0/en
Application filed filed Critical
Priority claimed from PCT/EP2021/052885 external-priority patent/WO2021156490A2/en
Publication of JP2023516280A publication Critical patent/JP2023516280A/ja
Publication of JP2023516280A5 publication Critical patent/JP2023516280A5/ja
Pending legal-status Critical Current

Links

JP2022548140A 2020-02-06 2021-02-05 コロナウイルスバインダー Pending JP2023516280A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202062971013P 2020-02-06 2020-02-06
US62/971,013 2020-02-06
US202062988610P 2020-03-12 2020-03-12
US62/988,610 2020-03-12
US202062991408P 2020-03-18 2020-03-18
US62/991,408 2020-03-18
US202063041240P 2020-06-19 2020-06-19
US63/041,240 2020-06-19
EPPCT/EP2020/077004 2020-09-25
EPPCT/EP2020/077004 2020-09-25
GB2020508.4 2020-12-23
GBGB2020508.4A GB202020508D0 (en) 2020-12-23 2020-12-23 Multivalent sars-cov-2 virus binders
EP21151356 2021-01-13
EP21151356.9 2021-01-13
PCT/EP2021/052885 WO2021156490A2 (en) 2020-02-06 2021-02-05 Corona virus binders

Publications (2)

Publication Number Publication Date
JP2023516280A JP2023516280A (ja) 2023-04-19
JP2023516280A5 true JP2023516280A5 (cg-RX-API-DMAC7.html) 2024-02-02

Family

ID=99799067

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548140A Pending JP2023516280A (ja) 2020-02-06 2021-02-05 コロナウイルスバインダー

Country Status (8)

Country Link
US (1) US20230227537A1 (cg-RX-API-DMAC7.html)
EP (1) EP4100055A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023516280A (cg-RX-API-DMAC7.html)
KR (1) KR20220166787A (cg-RX-API-DMAC7.html)
CN (1) CN116234569A (cg-RX-API-DMAC7.html)
AU (1) AU2021217563A1 (cg-RX-API-DMAC7.html)
CA (1) CA3166967A1 (cg-RX-API-DMAC7.html)
IL (1) IL295389A (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021252164B2 (en) 2020-04-09 2026-07-02 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
WO2021228854A1 (en) * 2020-05-11 2021-11-18 Lysando Ag Virus neutralization by soluble receptor fragments of the ace-2 receptor
AR123469A1 (es) * 2020-09-10 2022-12-07 Bighat Biosciences Inc DOMINIOS DE UNIÓN A LA GLICOPROTEÍNA ESPICULAR DEL SARS-CoV(-2) Y POLIPÉPTIDOS QUE LOS COMPRENDEN Y USO DE ESTOS
CN113755421B (zh) * 2021-09-28 2024-04-12 梦芊细胞因子有限公司 一种用于covid-19的口服性疫苗及抗体加强剂
EP4413122A4 (en) * 2021-10-07 2026-04-08 Seqirus Pty Ltd ANTI-SARS-CoV-2 ANTIBODIES AND THEIR USES I
WO2025033553A1 (ja) * 2023-08-10 2025-02-13 国立大学法人 東京大学 新規なhvem結合タンパク質およびそれを含む医薬組成物
CN117153245B (zh) * 2023-10-18 2024-03-19 无锡市疾病预防控制中心 预测新型冠状病毒S蛋白RBD区域与hACE2受体相互作用的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240515A1 (en) * 2003-07-21 2006-10-26 Dimitrov Dimiter S Soluble fragments of the SARS-CoV spike glycoprotein
CN101522208A (zh) * 2005-02-08 2009-09-02 纽约血库公司 抗严重急性呼吸综合征相关冠状病毒的中和单克隆抗体
ES2384497T3 (es) * 2005-02-08 2012-07-05 The New York Blood Center, Inc. Anticuerpos monoclonales neutralizantes contra el coronavirus asociado al síndrome respiratorio agudo severo
LT2285408T (lt) * 2008-06-05 2019-01-25 Ablynx N.V. Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui
WO2017196847A1 (en) * 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens

Similar Documents

Publication Publication Date Title
JP7453206B2 (ja) 改良された血清アルブミン結合剤
JP6850255B2 (ja) 抗−cd47抗体及びその使用
JP7195142B2 (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
US20050288491A1 (en) Super-humanized antibodies against respiratory syncytial virus
JP7663977B2 (ja) 抗pd―l1抗体およびその用途
JP2024150445A5 (cg-RX-API-DMAC7.html)
US10654943B2 (en) Tri-specific antibodies for HIV therapy
JP2018537966A (ja) Hiv感染症の予防または処置のための三重特異性および/または三価結合タンパク質
JP2018512138A5 (cg-RX-API-DMAC7.html)
JP2016529882A5 (cg-RX-API-DMAC7.html)
JP2010513539A5 (cg-RX-API-DMAC7.html)
KR101682040B1 (ko) Msrv 관련 질환에서 특이적 리간드의 치료적 용도
CN114736291B (zh) 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途
JP2018509889A5 (cg-RX-API-DMAC7.html)
US12173081B2 (en) CD19/CD38 multispecific antibodies
JP2023536654A5 (cg-RX-API-DMAC7.html)
WO2021148884A1 (en) Anti-wuhan coronavirus antibodies
JP2022512647A5 (cg-RX-API-DMAC7.html)
JP2022531556A5 (cg-RX-API-DMAC7.html)
JP2024506020A5 (cg-RX-API-DMAC7.html)
JP2025130076A5 (cg-RX-API-DMAC7.html)
JP2022529340A (ja) ヒトcd47を標的とする抗体
JP2023538518A5 (cg-RX-API-DMAC7.html)
JP2023553210A5 (cg-RX-API-DMAC7.html)
JP2024543134A5 (cg-RX-API-DMAC7.html)